Helping patients living with serious and rare diseases

Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases.

Our priority is to bring transformative medicines to patients by driving clinical program execution, understanding patient and physician needs, preparing the market, creating market access, and commercializing our products on a global basis.

Akcea, an affiliate of Ionis Pharmaceuticals, was established in early 2015 and based in Kendall Square in Cambridge, Massachusetts. Akcea has a robust portfolio of development- and registration-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Ionis standards of excellence.
Every Day Strengthens Our Impact

We continue to deepen our understanding of rare disease, which began with our pioneering work in complement biology. This knowledge allows us to innovate and evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives.

We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).
The Leading RNAi Therapeutics Company

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need.

Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 5 programs in late-stage clinical development.
original products based on recombinant DNA technology and molecular biology

Amgen, a world leader in biotechnology, has been exploring the power of scientific innovation to decisively improve patient’s lives for 30 years.

Amgen is on the cutting edge of developing original products based on recombinant DNA technology and molecular biology, having launched the first revolutionary biotechnology drugs. Today, Amgen is on the Fortune 500 list, helps millions of patients in the fight against serious diseases and continues to be true to its principles based on science.
First Portuguese Science and Technology Park specialized on Biotechnology

Biocant Park is the only Portuguese Science and Technology Park entirely devoted to Biotechnology. The park originated a dynamic research and business environment rarely seen in this sector in Portugal, perfect for innovation and knowledge exploitation.

Biocant Park provides a unique innovation ecosystem that covers the entire innovation pipeline, from the knowledge generation and human resources training to the market, including tech transfer, financing, scientific dissemination and industrial production.

The companies at Biocant Park represent around 40% of the total national number of biotech companies. The park provides a wide variety of services and opportunities to develop a competitive business.
Defeat devastating neurological diseases

Since our founding in 1978 as one of the world’s first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.

Millions of people around the world are affected by multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Many people also suffer from less common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP).

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.
Rare Opportunities, Personal Impact

At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.

Biotrend is a research-based company focused on the development, optimization, de-risking, integration and scale-up of bioprocesses for the production of bio-based chemicals, materials and fuels from renewable raw materials, including complex industrial by-products and wastes. We offer contract research and development services and develop new technologies to be licensed out to industrial clients. We actively participate in international collaborative projects encompassing the full bioeconomy value chain, keeping Biotrend at the forefront of scientific development.
National network of the marine bioresources value chain

The BLUEBIO ALLIANCE (BBA) is a national network that includes all subsectors of the marine bioresources value chain in Portugal. It ranges from raw material producers, R&D units, to biotech SMEs, transforming centers and manufacturers, public sector entities and support companies, up to the final consumer product developers. BBA aims at collectively organizing this value chain, to foster its relations and dynamics, leveraging its SMEs growth and accelerating their internationalization by increasing their outreach and exportations, leading to more jobs and value creation for Portugal.
We create value in a way that achieved results will endure

We are a private and independent financial advisory firm focused on wealth and asset management, private investments and setup of industrial strategies:

● Managing our clients wealth and in setting a long term investment approach to achieve their goals

● Supporting visionary entrepreneurs building great companies and in driving corporate growth

● Advising mergers and acquisitions, capital structuring and business strategies

BSIM Therapeutics is a biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of transthyretin-mediated amyloidoses. We work closely with patients and physicians to understand and answer to multiple clinical manifestations representing unmet medical needs.
Committed to improving the lives of patients worldwide

Everything we do at Celgene is focused on a singular mission of improving the lives of patients worldwide. In order to fulfill that promise, we understand that we must instill trust in our colleagues, our patients, our partners and the public at large through our words and our actions.

To that end, we take compliance and our corporate governance policies seriously. The compliance culture at Celgene is built on integrity, ethics, sound decision making and behaviors that sustain our values and commitment to patients.
Safe therapeutic and diagnostic solutions to treat cancer patients

CellmAbs is a biotech company focused on the discovery and development of cutting edge oncology products, aiming to deliver the most effective and safe therapeutic and diagnostic solutions to treat cancer patients. Our ultimate goal is to cure cancer and we work passionately everyday to achieve it.

Our team is comprised of renowned scientists and international experts in the field of glycoimmunology and oncology. We also maintain several partnerships and collaborations with national and international research centers and oncology clinical institutes.

The mission of Coimbra Genomics is to bring individualized medicine to the work environment of every physician. It has therefore developed ELSIE, a genome-based decision-making platform that allows the connection between genome knowledge and clinical practice, helping facilitate the making of important clinical decisions, adapted to the genetic characteristics of each user during normal visits to the doctor. ELSIE is being used on a pilot basis in several countries and began to be used clinically in Germany in 2016.
Focus on Serious & Rare Diseases

CSL Behring‘s parent company, CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL Behring and we are driven by our promise.

GenIbet is a biopharmaceutical CMO offering highly specialized Microbial, Cell Culture and Viral Process Development and cGMP manufacturing services to research groups, biotech and pharma companies. This, combined with in-house fill and finish capabilities, gives our clients the opportunity to go from bench to clinic in one facility.

GenIbet’s core activity is the manufacture and supply of materials for use in early stage drug development, pre-clinical studies and cGMP manufacturing from Phase I to Phase III clinical trials.
Dedicated to keeping people healthy

HeartGenetics is dedicated to keeping people healthy through the use of genetic information.

We help our clients define diet and exercise plans that improve health.

Based on more than 15 years of research in cardiovascular and bioinformatics, HeartGenetics’ R&D team developed new wellness genetic tests and reports that are instrumental in the definition of highly personalised lifestyle plans.

Founded in 2013, the company main goal is to play a key role in applied genetic knowledge and genetic testing, going into the wellness space.
Focused on building a sustainable society that provides equal opportunities

As part of the Calouste Gulbenkian Foundation, the Instituto Gulbenkian Ciência (IGC) is an institute dedicated to biological and biomedical research and innovative postgraduate training, placing science at the heart of society.

400 scientists, from 41 different nationalities, aim to understand the fundamental principles of Biology, in particular how the organism is formed and interacts with its environment, leading to novel approaches towards disease treatment and world sustainability.

Immunethep is a biotech startup company (spin-off from the University of Porto) that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections.

These therapies are the outcome of more than 30 years of research at the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) of the University of Porto.
A future where disease is a thing of the past

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension.
Unlock therapeutic solutions for the benefit of patients

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes – to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

Luzitin is a privately owned pharmaceutical company, focused on the development of photosensitizer compounds for Photodynamic Therapy (PDT).

Founded in 2010, after five years of research collaboration between Bluepharma, the University of Coimbra and the Hospitals of the University of Coimbra, Luzitin is developing a novel and very promising therapeutic procedure for solid tumors (LUZ11) and Acne (LUZACNE). Its proprietary technology consists of a combination of new generation photosensitizer with a specific infrared-laser medical device.
Help clients make strategic and financing decisions

We advise our clients in aligning their corporate and financial strategies with business goals, trends and best practices in the various markets in which they operate.

We monitor the optimization and maximization of the company value, through coordination of capital acquisition and sales transactions, as well as leveraged operations, execution of equity and debt raising processes and performing other related shareholders’ support advisory services, including acting as operating partner.
Breakthroughs begin with curiosity

Merck is a vibrant team of specialists in Healthcare, Life Science and Performance Materials. We share a love of science and a passion for technology.

We discover and develop for life in all its vibrancy, from great human questions to small everyday joys. For more than 350 years, curiosity has been driving us to deliver excellence to patients and our customers – and to imagine the future.
Woldwide solutions for molecular testing at point of care

NANO4 Global aims to provide solutions for one step molecular identification of DNA/RNA at point-of-care (PoC). NANO4 Global spins around an awarded platform — NANO4 – the next generation of molecular nanodiagnostics applied to lifesciences.
Precision Oncology Solutions For Liver Cancer

Ophiomics was born from a collaboration between scientists with clinicians sharing the purpose of bringing the latest advances in genomics, bioinformatics and clinical research in support of a Precision Oncology.

Ophiomics develops and offers advanced genetic and genomic tests in support of diagnostic, prognostic, pharmacogenomics and clinical follow up. We process both FFPE and Liquid Biospies (based on circulating cell free DNA) to characterise mutational landscapes of tumours, providing guidance for therapy and non-invasive assessments of response to treatment. We offer clinical testing to cancer centres alongside a strong emphasis in clinically-oriented research.
3D planning system for orthopedic surgery

In a relatively short lifetime, our company aims to hold on the forefront of innovation, through the creation of products that redefine services in Healthcare. We strive to build an unparalleled brand capable of developing engineering services for the community by creating innovative technological solutions which will improve the healthcare services, and increase the value of our clients, collaborators and partners.

PeekMed provides 3D orthopedic surgical planning tools. This technology helps the orthopedic surgeon to intuitively and freely manipulate the 3D model created through the imaging study of the patient. The osteosynthesis material of various companies can be added to the planning in the system, allowing the orthopedic surgeon to analyze the surgery’s impact.
Breakthroughs that change patients’ lives

Pfizer is one of the world’s premier innovative biopharmaceutical companies, discovering, developing and providing over 170 different medicines and vaccines healthcare products to help improve the lives of millions of people in the UK and around the world every year.

Our purpose is grounded in our belief that all people deserve to live healthy lives. This drives our desire to provide medicines that are safe and effective.
Extending life’s moments for patients with rare diseases and their loved ones

PTC has been successful over the years because our team is deeply committed to a single purpose: Extending life’s moments for patients with rare diseases and their loved ones. Our biggest accomplishments have always been measured by units of time – or “measured by moments.” Whether our therapies grant hours, days, months or years, every small moment is an enormous win.

Since 1998, PTC has been a biopharmaceutical company focused on innovative small molecule and gene therapies for rare genetic disorders. We operate offices and/or research labs in more than 20 countries and occupy a business footprint in more than 50 countries around the world. We also enjoy strong commercial performance and a robust capital position. Recently, we’ve expanded into oncology and virology therapeutic research.
Transforms scientific innovation into healthcare solutions

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
Marine pharmaceutical research and development

Sea4Us is world-class biotechnology company in marine pharmaceutical research and development that aims to discover treatments to respond to unmet clinical needs.
Computational Biology Solutions for the Life Sciences

SilicoLife develops state-of-the-art optimization algorithms and uses proprietary computational and modelling tools to accelerate the design of microbial strains, based on metabolic engineering and synthetic biology approaches, shortening the development time and costs of new highly effective processes for the production of specific target compounds such as biofuels, chemicals, food ingredients or biopolymers.
Rare Strength

Sobi is an international biopharmaceutical company focused on rare diseases. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases. 

We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Within Haematology, we have become a leading company in haemophilia, where we seek to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care.

Our Immunology portfolio, with three strongly growing products that each meet high unmet medical needs, represents a new focus that builds on our heritage in rare diseases. We continue to explore further external growth opportunities to strengthen our business and late-stage pipeline, so that we can continue giving more people living with rare diseases access to innovative treatments.
Your Easy Genetics Laboratory

Our mission is to be Your Easy Genetics Laboratory. Whether you are in Lisbon, Porto, Milano, Rio de Janeiro, Madrid, Cordoba, etc, we want to provide you (a patient, a doctor, a scientist, a veterinary professional or a student) an easily crossable bridge. We intend to create a fluid flow of your samples, data and information, supported by solid laboratories and high-qualify staff from STAB VIDA, always with the main purpose to give you the results you need.

Stemmatters is an ambitious regenerative medicine company developing game changing medical devices and combination products for large unmet medical needs.
Research and development centres on unique medical device development platforms, which offer excellent scope for tailoring biological and physicochemical performance for breakthrough applications in regenerative medicine. Fully integrated with specialized and resourceful competences in research and development, Stemmatters additionally offers unique manufacturing competences in regenerative medicine products for external entities.
Better Health, Brighter Future

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished history in Japan since 1781.